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High-dose parenteral iron sucrose depresses neutrophil intra-
cellular killing capacity.
Background. Iron is essential for the formation of hemoglo-
bin. During long-term treatment with human recombinant eryth-
ropoietin (rhEPO), the majority of end-stage renal disease
(ESRD) patients will not respond adequately to rhEPO unless
substituted with intravenous iron. However, concern exists
about possible detrimental effects of parenteral iron on cellular
host defense and iron-mediated increments of oxidative stress.
Methods. We analyzed phagocytic functions of polymorpho-
nuclear leukocytes (PMN) isolated from 20 ESRD patients on
peritoneal dialysis in response to 300 mg of iron sucrose or
placebo administered intravenously over two hours in a ran-
domized, double-blind manner. We evaluated FcR-dependent
phagocytosis and killing (primary outcome variable) of opso-
nized Escherichia coli, FcR-dependent oxidative burst capac-
ity, and complement receptor 3 (CR3, Mac1, CD11b/CD18)/
tumor necrosis factor alpha (TNF)-mediated release of bacte-
ricidal lactoferrin before, during, one hour, and two days after
administration.
Results. The absolute count and the percentage of E. coli
killed by PMN of iron sucrose–treated peritoneal dialysis pa-
tients decreased significantly over time in comparison to pla-
cebo-treated patients (F  3.48, df  4, P  0.008; F  3.99,
df  4, P  0.006, respectively). All secondary outcome vari-
ables were not different between both groups over time.
Conclusions. Killing capacity of PMN isolated from ESRD
patients decreases in response to high-dose parenteral iron
sucrose, possibly in part explaining reported higher hospitaliza-
tion rates and lower survival rates of dialysis patients receiving
frequent and high-dose parenteral iron.
Effective erythropoiesis requires both erythropoietin
and iron. Treatment with recombinant human erythro-
poietin (rhEPO) increases iron demands. Iron require-
ments may reach up to 50 mg/day [1]. Oral iron supple-
ments will not meet such high demands, as has been
shown for end-stage renal disease (ESRD) patients on
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peritoneal dialysis (PD) [2]. Therefore, iron is more fre-
quently administered parenterally during outpatient vis-
its. Parenteral iron preparations contain a central core
of elemental iron covered by a carbohydrate shell. Fol-
lowing intravenous administration the complex is metab-
olized, and iron is released and immediately scavenged
by serum transferrin [3]. Free iron has been detected
after parenteral administration of moderately dosed iron
to hemodialysis patients [4, 5], and concern exists [1]
about the oxidative stress implemented by circulating
transition metals such as iron [6]. A recent analysis of
more than 5800 U.S. hemodialysis patients in 1994 found
a diminished survival rate and higher rates of hospitaliza-
tion for patients with more intense iron dosing, even after
extensive correction for potential confounding baseline
demographics and comorbidity [7]. This confirmed ear-
lier investigations [abstract; Collins A, Ebben J, Ma J, J
Am Soc Nephrol 8:190A, 1997; abstract; Collins A et al,
J Am Soc Nephrol 9:204A, 1998]. However, in a French
multicenter prospective study neither parenteral iron nor
serum ferritin, possibly indicating iron overload, was associ-
ated with an increased risk of infection [8]. Iron overload
has been associated with increased numbers of infectious
events [9–11], and polymorphonuclear leukocytes (PMN)
phagocytic functions appear to be depressed in patients
with iron overload [12–15].
Phagocytes play a pivotal role in cellular host defense.
Following phagocytic internalization pathogens are de-
graded by a series of coordinated events, such as granule
fusion, activation of nicotinamide adenine dinucleotide
phosphate (NADPH)-oxidase, and others. Killing of
pathogens was long attributed to the immediate toxicity
of NADPH-oxidase–generated reactive oxygen species
(ROS), and myeloperoxidase (MPO)-derived hypo-
chlorus acid was thought to damage bacterial proteins
by chlorination. However, ROS generation and MPO
activity are not sufficient themselves to kill target organ-
isms [16]. Bacterial killing appears to depend on the
ROS-mediated solubilization of granule-contained pro-
teases and bactericidal proteins, such as cathepsin G,
elastase, and lactoferrin [16]. The latter two were found
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to kill gram-negative bacteria by degrading outer mem-
brane proteins [17–19]; however, iron saturation of lacto-
ferrin reverses such actions [17, 20].
We hypothesized that PMN phagocytic functions, in-
cluding killing capacity, might become depressed during
high-dose parenteral administration of iron. Up to 300
mg of iron sucrose may be safely given over two hours
[21]. Higher doses have been reported to convey an
increasing risk of adverse reactions [22]. We performed
a randomized trial, comparing 300 mg of parenteral iron
sucrose to placebo in PD patients. We isolated and incu-
bated PMN of both iron sucrose– or placebo-treated PD
patients in the presence of opsonized Escherichia coli,
thus primarily inducing FcR engagement. Second, we
costimulated PMN by fibrinogen in conjunction with tu-
mor necrosis factor alpha (TNF), thus mobilizing CR3
(Mac1, CD11b/CD18), inducing adherence and subse-
quently, the release of ROS and lactoferrin [23]. Both
assays may provide functional data on two different
mechanisms of how iron possibly depresses PMN phago-
cytic functions.
METHODS
Objective and outcome variables
It was the objective of this study to evaluate the imme-
diate influence of parenteral iron sucrose on the PMN
functions phagocytosis and intracellular killing of opso-
nized E. coli (primary outcome variable count and per-
centage of killed E. coli/PMN). The count of viable E.
coli/PMN, the count of phagocytozing PMN, the count
of phagocytosed E. coli/PMN, the oxidative burst, and
the stimulated degranulation of the secondary granule
constituent lactoferrin served as secondary outcome vari-
ables. All parameters were expected to decrease during
observation.
Study design and intervention
After approval by the local medical ethics committee
a prospective, randomized, double-blind placebo-con-
trolled study was performed at the Department of Ne-
phrology and Dialysis, University Hospital Vienna, from
May 7, 2001, to February 20, 2002. Patients who had
been on peritoneal dialysis for at least 3 months, older
than 19 years of age, not taking any immunosuppressive
medications, with a hemoglobin 13 g/100 mL (prelimi-
nary inclusion criteria) were considered eligible for par-
ticipation. After written informed consent was obtained
intravenous iron supplementation was stopped and rhEPO
therapy was continued without further adjustments to
the degree of anemia. Participants were screened for
inclusion criteria (hemoglobin 11 g/100 mL, ferritin
200 g/L, transferrin saturation50%) during follow-
up routine outpatient visits at 3- to 4-week intervals.
Exclusion criteria included a known adverse reaction to
iron sucrose, serum-transaminases three times greater
than the upper normal value, pregnancy or breast-feed-
ing, signs of infection, a serum-ferritin1000g/L, trans-
ferrin saturation50%, or participation in another clini-
cal investigation. When inclusion criteria were met, patients
entered the active study phase and received study medi-
cation either at the peritoneal dialysis or at the nephrol-
ogy outpatient day clinic within 2 to 6 days. Some patients
exhibited marginally higher hemoglobin or ferritin values
than were set for inclusion, either on the day of screening
before or on day 1 of the study. However, all patients’
laboratory values lay within inclusion limits either 2 to
6 days before or on day 1. Study medication consisted
of a 2-hour intravenous infusion of either 300 mg of iron
sucrose (Venofer) dissolved in 50 mL of normal saline
or of 50 mL of normal saline. From the various iron
preparations available we chose iron sucrose to challenge
PMN activities; in contrast to other iron preparations iron
sucrose does not bear the potential risk of anaphylactic
reactions [3], and doses of up to 300 mg may be safely
given over 2 hours [21]. According to the European Best
Practice Guidelines [1], up to 500 mg of iron sucrose
are recommended in the PD setting, depending on the
degree of anemia and iron deficiency. The flow of study
participants is presented in Figure 1. Blood for the deter-
mination of PMN parameters was drawn at t  0, 30,
120 (end of infusion), and 180 minutes (day 1), and after
48 hours (day 3). Participants were allowed to consume
a small meal and beverages, if requested, during infusion.
Sample size, randomization, blinding, and participants
In a pilot study, six anemic end-stage renal disease
patients received 300 mg of iron sucrose over 2 hours
intravenously. Since we observed a reduction of PMN
intracellular killing capacity over time but no influence
on other PMN parameters, PMN killing was chosen as
primary outcome variable. Based on a decrease from
4.4  0.9 to 3.1  0.8 of intracellularly killed E. coli at
the end of the infusion we calculated a sample size of
10 participants per group with a power of 90% and an
alpha level of 5% [24]. Random allocation sequence was
generated by Marcus Mu¨llner (MM) using a table of ran-
dom numbers (MM was not involved in recruitment or
treatment of patients), implemented by closed envelopes
to be opened on day 1 of the active study phase (
administration of study medication). The envelopes were
opened immediately before preparation of study medica-
tion by medical staff neither involved in the administra-
tion of study medication nor in laboratory evaluations
at outpatient clinics. Study participants, medication ad-
ministering doctors, and laboratory personnel assessing
PMN parameters were blinded to group assignment.
Study medication was administered by doctors blinded to
treatment via nontransparent black syringes and infusion
sets. Ten patients were randomly allocated to receive
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Fig. 1. Flow diagram of subject progress.
iron sucrose (median age, 44 years; range, 30 to 63; 2
female) and ten patients received placebo (median age,
50 years; range, 34 to 73; 6 female). Due to the small
sample size no efforts were made to correct for possible
group heterogeneity by stratification. Median time on
peritoneal dialysis was 19.0 months (3.5 to 76.2) in the
iron group versus 14.5 months (3.0 to 44.8) in the placebo
group. In the iron group, 3 out of 10 patients performed
nightly intermittent peritoneal dialysis (NIPD); 6 out
of 10 performed continuous cycler peritoneal dialysis
(CCPD), and 1 out of 10 performed continuous ambula-
tory peritoneal dialysis (CAPD). In the placebo group,
1 out of 10 performed NIPD, 4 out of 10 performed
CCPD, and 5 out of 10 performed CAPD. Patients on
CCPD and CAPD received study medication with a full
abdomen; patients on NIPD received medication ap-
proximately 3 hours after emptying the peritoneal cavity.
Dwell fluid contained 1.36% glucose. In the iron group
2 out of 10 patients were smokers in comparison to 1
out of 10 in the placebo group; 1 out of 10 patients had
diabetes mellitus in the iron group, compared to 3 out
of 10 in the placebo group. No participant had a known
history of chronic alcohol abuse. Nutritional status as
judged in accordance with the 7-point Likert scale by
subjective global assessment was comparable in both
groups, with 5 patients scoring 5 to 7 and 3 to 5 points,
respectively, in each group. Median serum albumin con-
centration was 36.6 g/L (26.0 to 40.8) in the iron group
versus 34.4 (27.3 to 38.8) in the placebo group; median
protein catabolic rate 1.04 g/kg/day (0.69 to 1.3) in the
iron group versus 0.99 (0.59 to 1.36) in the placebo group.
Minimal time interval between the latest peritonitis epi-
sode and study intervention was 6 months. Basal labora-
tory data were collected at the outpatient clinics and
PMN data were accumulated by laboratory personnel.
The active phase was terminated after study participants
returned to the outpatient clinic on day 3 for the final
blood sample to be drawn.
PMN isolation
PMN were isolated at each time point immediately
after collection of the blood sample. Heparin anticoagu-
lated blood was mixed 1:1 with normal saline, underlay-
ered by Ficoll-Paque Plus (Amersham, Uppsala, Swe-
den), and then centrifuged for 30 minutes at 450g. The
supernatant containing lymphocytes and monocytes was
removed, the red pellet containing erythrocytes and
PMN was suspended in lysis buffer [168 mmol NH4CL,
10 mmol KHCO3, 0.1 mmol ethylenediaminetetraacetic
acid (EDTA)-Na2, pH 7.3] and incubated on ice for about
10 minutes until lysis of erythrocytes occurred (color
change from light red to transparent dark). After centrif-
ugation for 10 minutes at 250g, 4C, the pellet was resus-
pended in lysis buffer, centrifuged again, and then
washed twice in the buffer used in the functional assay.
Composite measurement of phagocytosis and
intracellular killing
The assay was performed as previously described [15,
25, 26]. The Escherichia coli strain Amercian Type Cul-
ture Collection 25922 was grown overnight in 3 mL of
Columbia broth (Life Technologies, Paisley, UK). After
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harvesting and washing the cells with Hank’s buffer, 108
E. coli cells/mL were opsonized by incubation with 1/10
vol of homologous serum for 30 minutes at 37C. After-
wards, 200 L of PMN (107/mL) and 200 L of E. coli
cell suspension (108/mL) were incubated for 30 minutes
at 37C. One mL of ice-cold Hank’s buffer was added
to stop phagocytosis, PMN were pelleted by centrifuga-
tion (7 minutes at 160g), and, after removal of the super-
natant, stained by adding 200 L of acridine orange (1.44
mg/mL of Hank’s buffer) for 1 minute. After addition
of 1 mL of ice-cold Hank’s buffer, 0.5 mL of this suspen-
sion was cytospinned, the supernatant was removed, and
phagocytosis and intracellular killing were evaluated un-
der fluorescence microscope by counting 3 to 4 high-
power fields, stopping after 100 PMN; acridine orange
differentiates viable from dead bacteria due to a shift
in emission peak from green to orange with increasing
intercalation of acridine orange into less structured DNA
of the dead cell [27]. All specimens were evaluated by
the same blinded observer; the coefficient of variation
was 4.9% (killed E. coli/PMN), 1.8% (percentage killed
E. coli), 4.7% (viable E. coli), 2.7% (phagocytozing
PMN), and 3.4% (phagocytosed E. coli/PMN).
Oxidative burst
Determination of PMN oxidative burst was carried
out in heparinized blood by flow cytometry (Bursttest;
Opregen Pharma, Heidelberg, Germany). After stimula-
tion by opsonized E. coli or phorbol 12-myristate 13-
acetate (PMA; Sigma Chemical Co., St. Louis, MO,
USA), the irreversible oxidation of the fluorogenic sub-
strate dihydrorhodamine 123 to rhodamine 123 by PMN-
generated hydroxyl radicals is detected quantitatively.
Degranulation of lactoferrin
PMN were plated on a fibrinogen-coated surface, where
they adhered, spread, and released granule constituents
over time as described by Nathan [28] and Suchard and
Boxer [23]. Fibrinogen (ICN Pharmaceuticals, Costa
Mesa, CA, USA, 50 g/mL Hank’s buffer) was absorbed
onto Falcon Primaria 96-well tissue culture plates (Bec-
ton Dickinson, Franklin Lakes, NJ, USA) for 60 to 90
minutes in a tissue culture incubator at 37C 5% CO2.
After washing the plates with Hank’s buffer three times,
each well was equilibrated with 140 L of minimum
essential medium (MEM; Gibco, Paisley, UK)  TNF
(ICN, Ohio, USA) or PMA for 20 to 30 minutes before
addition of 10 L of 1.5 	 106 PMN/mL MEM. PMA
stimulation served as a positive control, indicating func-
tionally active PMN. The number of PMN per well was
on the linear portion of the concentration-response curve
for detectable lactoferrin release; the final concentra-
tions of TNF (20 ng/mL) and PMA (100 ng/mL) yielded
maximal responses (data not shown). Within 30 to 60
minutes PMN began to attach to the fibrinogen-coated
surface and finished spreading by 90 to 120 minutes,
Fig. 2. Unstimulated (dashed line) and CR3/TNF-stimulated (solid
line) release of lactoferrin by adhering PMN of one study participant
throughout the active study phase (0 minutes to 48 hours). Study medica-
tion was administered over 2 hours (shaded area, 0 to 120 minutes),
blood for the isolation of PMN and subsequent analysis of lactoferrin
release was sampled at t  0, 30, 120, 180 minutes, and 48 hours. In
vitro lactoferrin release was estimated over 2 hours in intervals of 30
minutes. For further analysis, the area under each curve was calculated
using the trapezoid rule [29]. Abbreviations are: TFN, tumor necrosis
factor alpha; PMN, polymorphonuclear leukocytes.
as has been published for N-formyl-methionyl-leucyl-
phenyalanine (fMLP)-stimulated PMN [23]. At t  0,
30, 60, 90, and 120 minutes supernatants were transferred
to a sterile 96-well microtiter plate in triplicate, nonad-
herent PMN were pelleted by centrifugation at 4C 250g
for 5 minutes, and cell-free supernatants were stored at

70C until further processing.
Figure 2 shows an assay synopsis of one study patient
over time. For statistical calculations, released lactofer-
rin/105 PMN was calculated as the area under each curve
[29] divided by the duration of the assay (120 minutes),
yielding ng lactoferrin/105 PMN/minute.
Estimation of lactoferrin
Lactoferrin concentrations were assayed by enzyme-
linked immunosorbent assay (ELISA) technique using
a commercially available polyclonal rabbit anti-human
as primary antibody (Dako, Copenhagen, Denmark) and
a peroxidase-conjugated, rabbit anti-human lactoferrin
antibody (Jackson, West Grove, PA, USA) for antigen
detection as described previously [30, 31].
Only iron-free lactoferrin exerts bactericidal effects
[17, 20]. We speculated upon a possible increase of lacto-
ferrin-bound iron during intravenous iron supplementa-
tion but attempts to measure iron in supernatants of
degranulating PMN by graphite furnace atomic absorp-
tion spectrometry failed (limit of detection, 0.5 ppb; Per-
kin Elmer 4001 ZL, Norwalk, CT, USA; wavelength,
248.3 nm; pretreatment temperature, 14,000C; atomiza-
Deicher et al: Parenteral iron depresses PMN killing732
tion temperature, 21,000C); iron concentrations were
below the detection limit (personal communication, M.
Zeiner, I. Steffan, 2002, data not shown).
Statistical analysis
We present continuous data as median and the range
and counts only as absolute frequencies, as there were
only 10 patients per group. To display the outcomes’
course over time between the groups, we present medi-
ans and the corresponding 95% confidence intervals.
Two-way repeated measurement analysis of variance
(ANOVA) was used to assess whether the outcome vari-
ables differed between the groups and if the association
between the outcome variables and the exposure (ad-
ministration of iron) varied over time. To allow for serial
correlations between the successive observations on the
same subject we used the Greenhouse and Geisser epsi-
lon to derive corrected P values for within subject com-
parisons [32, 33]. The outcome variables investigated
included killed E. coli/percentage killed E. coli (primary
outcome); viable E. coli/PMN, phagocytozing PMN, and
phagocytosed E. coli/PMN; basal, TNF-, and PMA-
stimulated release of lactoferrin; and basal, E. coli– and
PMA-stimulated “oxidative burst.” We calculated one
model for each of these outcomes. When the distribution
of some variables was skewed to the right we used log
transformation to fulfill the assumptions of normality for
our repeated ANOVA models. We used Stata (Stata
Corporatioin, College Station, TX, USA), release 7, for
the analysis.
RESULTS
Thirty-six end-stage renal disease patients attending
the peritoneal dialysis outpatient clinic fulfilled the pre-
liminary inclusion criteria defined above; 31 gave in-
formed consent to stop ongoing iron substitution. During
two to seven months of follow-up, two patients had to
be withdrawn due to renal transplantation, three patients
developed infectious complications, and six failed to
reach the target hemoglobin of 11 mg/100 mL within
the observation period (Fig. 1). Finally, 20 patients were
randomly allocated to receive either iron sucrose (N 
10) or placebo (N  10). All 20 patients completed the
study and were analyzed for primary and secondary out-
come variables by intention-to-treat. No adverse events
were recorded. One study participant was hospitalized
because of peritonitis four days after receiving iron su-
crose (one day after the study ended); this patient per-
formed peritoneal dialysis for more than six years, with
three episodes of peritonitis prior to study enrollment,
carried significant comorbidities (chronic hepatitis C,
cardiomyopathy), and was malnourished, scoring 3 out
of 7 points on the Likert scale for subjective global assess-
ment. Table 1 summarizes patients’ characteristics.
Association between killing capacity and the
administration of iron sucrose
The primary outcome variable killed E. coli was com-
parable at baseline in both groups (Fig. 3 A and B). The
number of killed bacteria and the percentage of killed
bacteria changed significantly over time between the
groups (killed, F  3.84, df  4, P  0.008; percentage
killed, F 3.99, df  4, P  0.006). The overall percent-
age of killed E. coli was lower in the iron sucrose treat-
ment group (F  6.59, df  1, P  0.019).
Association between secondary outcome variables and
the administration of iron sucrose
Viable E. coli was slightly, but statistically not signifi-
cantly higher in the iron treatment group (F 4.14, df
1, P  0.057). This difference did not vary over time
between the groups (F  0.44, df  4, P  0.77), even
though viable E. coli increased in both groups (F 4.61,
df 4, P 0.0073) (Fig. 3C). Percentage of phagocytoz-
ing PMN changed over time within subjects (F  3.18,
df  4, P  0.04) but there was no difference between
the groups over time (F  1.31, df  4, P  0.28). The
number of phagocytosed E. coli/PMN did not change
over time within subjects (F  0.68, df  4, P  0.54)
or between groups over time (F  1.5, df  4, P  0.23).
Basal release of lactoferrin varied over time in both
groups within subjects (F  5.4, df  4, P  0.003), but
there was no difference between the groups over time
(F  1.4, df  4, P  0.25) (Fig. 4A). This was also true
for TNF-stimulated lactoferrin release (within subjects
over time, F  2.98, df  4, P  0.025; between groups
over time F  1.61, df  4, P  0.18) (Fig. 4B). PMA-
stimulated release was stable over time within subjects
and between the groups (F  0.97, df  4, P  0.43;
F  0.38, df  4, P  0.55).
Basal oxidative burst capacity did not change over
time between subjects (F  1.94, df  4, P  0.12) and
was similar in both groups (F  0.14, df  1, P  0.71).
E. coli, as well as PMA-stimulated oxidative burst, were
stable over time within subjects and comparable between
groups (E. coli within subjects over time, F  1.31, df 
4, P  0.28; E. coli between groups, F  0.11, df  1,
P 0.75; PMA within subjects over time, F  1.68, df
4, P  0.19; PMA between groups, F  0.02, df  1,
P  0.89).
DISCUSSION
Interpretation of study results in relation to
study hypothesis
We used a rigorous prospective randomized, placebo-
controlled double-blind design to challenge our study
hypothesis. When compared to placebo, the number and
percentage of killed E. coli/PMN obtained from PD pa-
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Table 1. Median laboratory parameters of study participants 2 to 6 days before (pre), on day of infusion (day 1), and 14 to 20 days after
(post) receiving either parenteral iron sucrose (N  10, iron sucrose) or normal saline (N  10, placebo)
Iron sucrose Placebo
Pre Day 1 Post Pre Day 1 Post
HBa g/100 mL 10.8 (10.2–11.7) 11.3 (8.8–12.3) 10.2 (9.4–11.8) 10.6 (9.9–11.4) 11.2 (9.9–11.9) 11.1 (10.3–12.8)
HCT % 31.5 (25.3–37.1) 33 (31.2–36.8) 32.1 (28.1–36.4) 33.4 (30.2–36.8) 31.9 (25.3–34.7) 35.7 (31.6–37.8)
WBC g/L 6.9 (5–8.2) 6.9 (4.2–9) 6.0 (5.1–9.2) 6.9 (4.1–9.1) 5.5 (3.7–10.3) 7.0 (4.4–9.3)
CRP mg/100 mL 0.5 (0.5–1.6) 0.6 (0.5–1.6) 0.5 (0.5–2) 0.5 (0.5–1.7) 0.5 (0.5–1.7) 0.9 (0.5–2.8)
Iron lg/100 mL 50 (18–126) 57 (22–114) 59 (24–130) 58 (26–77) 59 (25–76) 49 (20–76)
TF mg/100 mL 203 (130–237) 205 (157–287) 197 (155–217) 189 (144–273) 168 (148–268) 180 (147–310)
TSAT % 17 (10–48) 17 (10–45) 26 (9–59) 20 (9–35) 19 (10–30) 18 (7–29)
Ferritina lg/L 119 (18–290) 115 (15–170) 150 (17–244) 84 (26–378) 131 (43–151) 83 (11–164)
Abbreviations are: HB, hemoglobin; HCT, hematocrit; WBC, white blood cell count; CRP, C reactive protein; TF, transferrin; TSAT, transferrin saturation. CRP
levels  0.5 were arbitrarily set to 0.5. Numbers in brackets indicate range.
a Median and range values higher than set for inclusion are due to higher values of single patients either 2 to 6 days before or on the day of study intervention
tients decreased in response to high-dose parenteral iron
sucrose. When compared over time, a direct impact of iron
sucrose is suggested; the decreased killing was observed
only at the end of iron sucrose infusion (at 120 minutes)
and one hour after cessation of the infusion, but not two
days later (Fig. 3A and B). We conclude that PMN intra-
cellular killing capacity decreases during high-dose par-
enteral iron sucrose. Accordingly, the number of viable
E.coli/PMN was higher in the iron treatment group (Fig.
3C). This effect, however, was statistically not significant
(P  0.057), which most likely reflects a lack of power
for secondary outcomes. When analyzed over time the
number of viable E. coli increased significantly in the iron
group and, unexpectedly, in the placebo group. Never-
theless, our findings provide evidence in favor of our
study hypothesis.
No clear-cut effect was observed for all secondary
outcome variables. Therefore, the mechanism by which
iron may depress PMN killing capacity remains unclear.
The variables count of phagocytozing PMN, count of
phagocytosed E. coli/PMN, and E. coli–stimulated re-
lease of ROS all depend on FcR-engagement, the latter
of which appears functionally unaffected by intravenous
iron therapy. Solubilization of lactoferrin lies down-
stream to the generation of ROS, TNF promotes neu-
trophil ROS production and lactoferrin release via up-
regulation of CR3 [23], but has no effect on ROS
production induced by FcRIIa or FcRIIIb [34]. Since
our sample size was small and the variable TNF-stimu-
lated release of lactoferrin varied significantly over time
in both groups, we could have overlooked some effects
of iron on CR3-dependent signaling (type II error). PMA
stimulation reflects receptor-independent activation of
protein kinase C. Therefore, the stable response to PMA
over time in both groups does not argue against such
tentative interpretation.
Methodologic considerations, strengths, and limitations
PMN phagocytic functions were evaluated by a com-
posite measure, allowing simultaneous quantification of
phagocytosed and killed bacteria by visual inspection
after staining with acridine orange. Alternative methods
including microbiologic assays relying on plating or in-
corporation of [3H]-thymidine after coincubation may
overestimate killing due to misjudging growth-arrested
bacteria as dead [26]. Our endpoint “DNA denatur-
ation” lies downstream of growth arrest. Consequently,
we might have measured killing in a less sensitive man-
ner, underestimating rather than overestimating our end
point [26]. Flow cytometric methods are hampered by
difficulties in relating fluorescence intensity to the num-
ber of ingested bacteria. Visual inspection is time-con-
suming and tedious, bearing the potential risk of count-
ing errors. However, our coefficient of variation was
small and in a commonly accepted range.
The strength of our study lies in the rigorous prospec-
tive, placebo-controlled double-blind design allowing
control of possible biases by participants, observers, and
further confounding variables. We focused on the homog-
enous subset of patients on PD for at least three months
and not taking any immunosuppressive medications; he-
modialysis and several immunosuppressive agents may
alter PMN functions to a great extent. Because of the small
sample size baseline differences could not be accommo-
dated in the analysis. Accordingly, we cannot exclude a
potential confounding by such differences. However, the
baseline data are comparable between both groups, and
we incorporated serial measurement of the end points
using repeated measurement ANOVA for analysis.
In the present study, we provided functional data on
iron-mediated cellular dysfunctions. However, all our
assays are in vitro methods, only in part reflecting physio-
logic settings. In particular, our assay for the evaluation
of CR3-mediated release of lactoferrin is artificial. This
assay may serve as a measure of how much lactoferrin
may be maximally mobilized by challenged PMN. The
absolute concentration we found of lactoferrin/105 PMN
isolated from healthy donors was within the range re-
ported for fMLP-stimulated PMN [23], thus validating
our assay including ELISA measurements of lactoferrin.
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Fig. 3. Median number of killed E. coli/PMN (A ), median killed E.
coli in % of total number of phagocytosed E. coli/PMN (B ), and
median number of viable E. coli/PMN (C ) at t 0, 30, 120, 180 minutes,
and 48 hours after parenteral administration of 300 mg of iron sucrose
() or placebo (). Bars indicate the corresponding 95% confidence
intervals. Inserts indicate the level of significance of the treatment-time
interaction. PMN, polymorphonuclear leukocytes.
Interpretation of study results in view of current findings
Defective PMN phagocytic functions have long been
observed in uremia and a number of reports dating back
to the pre-erythropoietin era related these defects to
iron overload favoring bacteremia [9–11]. Hoen et al [11]
initially identified a serum ferritin level 500 ng/mL as
Fig. 4. Median released lactoferrin by PMN in the absence (A ) or in
the presence of concurrent stimulation with 20 ng/mL TNF (B) at t 
0, 30, 120, 180 minutes, and 48 hours after parenteral administration
of 300 mg of iron sucrose () or placebo (). Bars indicate the corre-
sponding 95% confidence intervals. Lactoferrin is expressed as the
median area under the curve (see Fig. 2) divided by duration of the
assay (120 minutes), yielding ng lactoferrin/105 PMN/minute. Inserts
indicate the level of significance of the treatment-time interaction. PMN,
polymorphonuclear leukocytes; TFN, tumor necrosis factor alpha.
an independent risk factor for bacterial infections, but in
a subsequent large sized, prospective multicenter study
neither serum ferritin nor iron-treatment could be identi-
fied as significant risk factors [8]. Patruta et al [15] de-
scribed a markedly decreased intracellular killing capac-
ity of PMN isolated from hyperferritinemic (650 g/L)
end-stage renal disease patients on chronic hemodialysis.
In addition, PMN of these patients exhibited a reduction
of oxidative burst capacity in comparison to the already
reduced oxidative metabolism of polytransfused, iron-
overloaded patients. The number of phagocytosed bacte-
ria/PMN was unaltered in comparison to healthy or iron-
overloaded subjects similar to our present observations.
Several studies have shown significantly reduced phago-
cytosis in uremic versus healthy subjects [35–38], perhaps
due to abnormalities of the neutrophil FcR [39]. Phago-
cyte function was impaired after incubation with ferric
citrate [40]. We did not observe differences in FcR-
dependent phagocytosis after intravenous iron loading
in PD patients. Calcium channel blockade was shown to
correct defective phagocytosis [38]. Eight out of 10 of
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our study participants were on continuous oral therapy
with a calcium channel antagonist. Nevertheless, high-
dose parenteral iron therapy depressed PMN killing in
these patients.
Generalizability of the trial data
A retrospective cross-sectional study of United States
Renal Data System and linked Medicare data analyzed
a sample of 5833 U.S. dialysis patients [7]. The authors
could show a statistically elevated rate of both hospital-
ization and death if 10 vials of 100 mg iron dextran
per 6 months were billed. Other investigators found an
increased risk of death from any cause, as well as from
infection, when comparing hemodialysis patients receiv-
ing more frequent and high-dose intravenous iron sup-
plements to patients on less intense iron regimens [ab-
stracts, Collins A, Ebben J, Ma J, J Am Soc Nephrol
8:190A, 1997; Collins A et al, J Am Soc Nephrol 9:204A,
1998]. In the Normal Hematocrit Trial the risk for all-
cause mortality was increased in patients assigned to the
“normal hematocrit” goup targeted to a hematocrit of
42% [41]. Since the latter received significantly more
rhEPO, as well as parenteral iron, and because infection-
related mortality was increased, a possible cause (iron)-
effect (mortality) relation might be inferred, although
these patients had lower ferritin levels in comparison.
However, multivariate analysis of baseline covariates
was not performed, and due to the post hoc nature of
the analysis, the validity of such a conclusion remains
unclear. No differences in hospitalizations or infection
rates were noted in a small-sized, single-center, random-
ized, prospective study on maintenance hemodialysis
patients receiving significantly more or less intense par-
enteral iron therapy in order to optimize rhEPO con-
sumption [42]. Further studies confirmed the safety of
parenteral iron with respect to side effects and infectious
complications. However, the validity of these data is ham-
pered by a lack of control group, small study size and
short observational period, absence of a priori definition
of end points, and low-dose iron [2, 43].
Our results demonstrate that high-dose parenteral
iron depresses PMN killing capacity, possibly explaining
in part why frequent and high-dose parenteral iron may
be associated with an increased infectious mortality of
hemodialysis patients. Impairment of PMN intracellular
killing of Staphylococcus aureus was shown to precede
nosocomial infections in critically ill patients [44] and E.
coli strains isolated from hospitalized patients during
bacteremia were more resistent to killing by rat perito-
neal cells from patients developing additional multiorgan
failure [45]. Both observations, in conjunction with our
data, point to a clinically relevant meaning of an in vitro
analysis of phagocyte killing capacity.
CONCLUSION
The dose of 300 mg of iron sucrose lies well within
the range of clinical demands and follows current guide-
lines [1]. Caution is warranted when generalizing data
from a small-sized study like ours. Significant amounts
of free iron have been detected after parenteral adminis-
tration of 100 mg of iron sucrose [abstract; Banyai S et
al, J Am Soc Nephrol 9:198A, 1998], but no free iron
was detected after administration of less than 100 mg of
iron sucrose. Others reported a transient oversaturation
of transferrin in more than 90% of patients receiving
sodium ferric gluconate in doses of 62.5 to 125 mg during
the final 30 minutes of hemodialyis [4]. Lim et al [46]
noted significantly decreased plasma superoxide dismu-
tase activity and increased plasma levels of malondialde-
hyde following intravenous administration of 100 mg of
iron sucrose to hemodialysis patients, indicating incre-
ments in acutely generated, iron-mediated oxidative stress.
In particular, effects were more pronounced in patients
with elevated ferritin levels (600 g/L), suggesting that
replete cellular iron stores alleviate free radical toxicity
after intravenously administered iron, possibly due to
higher levels of free, chelatable iron. Antioxidants such
as -tocopherol and melatonin were shown to prevent
iron-induced increments in oxidative stress [5, 47]. If the
latter was the mediator of iron-induced cellular dysfunc-
tions, antioxidative agents should have a beneficial effect.
However, larger-sized prospective, randomized controlled
trials with clinical end points are needed to confirm such
interpretations of our findings.
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